Levodopa Benefits Neovascular Age-Related Macular Degeneration
TUESDAY, Sept. 15, 2020 -- Levodopa is a safe and well-tolerated treatment for neovascular age-related macular degeneration (nAMD) and improves visual outcomes, according to a study recently published in The American Journal of Medicine.
Anna G. Figueroa, from the University of Arizona in Tucson, and colleagues examined the effect of levodopa in nAMD. In cohort 1, the effects of carbidopa-levodopa were assessed on vision and anatomic outcomes for four weeks among patients with newly diagnosed nAMD and naive to anti-vascular endothelial growth factor (VEGF) injections. In cohort 2, patients previously treated with anti-VEGF injection therapy were treated with ascending levodopa doses.
The researchers found that levodopa was safe and well tolerated and improved visual outcomes while delaying anti-VEGF injection therapy. Retinal fluid decreased by 29 percent without anti-VEGF treatment in the first month. The decrease in retinal fluid was sustained through six months, with a mean anti-VEGF injection frequency of 0.38 injections/month. Mean visual acuity improved by 4.7 and 4.8 letters in cohorts 1 and 2, respectively. In cohort 2, there was a 52 percent reduction in the need for anti-VEGF injections.
"Using levodopa as an adjuvant therapy for nAMD could well alter the course of disease progression and save billions of dollars without sacrificing vision," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: September 2020
Read this next
WEDNESDAY, May 27, 2020 -- A new artificial intelligence algorithm can predict risk for age-related macular degeneration (AMD), according to a study published in the April issue of...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.